In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

Table 1 The scenarios modeled¹

Scenario (S#)	Class	# shRNA	Efficacy (%)	HSC+ (%)	Fitness (%)
S0	Untreated
S1	I & II	6	80ⁿ	20	99
S2	I & II	4	80ⁿ	20	99
S3	I & II	2	80ⁿ	20	99
S4	I & II	6	60ⁿ	20	99
S5	I & II	6	80ⁿ	1	99
S6	I & II	2	80ⁿ	20	50
S7	I & II	2	80ⁿ	1	50
S8	I & II	6	80ⁿ	20	90
S9	I & II	6	80ⁿ	20	50
S10	I & II	2	80ⁿ	20	90
S11	II only	6	80ⁿ	20	99

¹Twelve scenarios (S#) varied in the number of shRNAs considered (6, 4 and 2 shRNAs), the efficacy of each shRNA (60 or 80%), the proportion of hematopoietic stem cells transduced with the gene therapeutic (HSC+; 20 or 1%), viral fitness (99, 90, or 50%), and the class of treatment (Class I and II). The untreated control (S0) contained only UNTx cells exposed to HIV.

ISSN: 1742-4690